High impact of chemotherapy on ovarian reserve in breast cancer survivors of reproductive age: A systematic review and meta-analysis.

ABSTRACT:

Introduction

The risk of infertility following breast cancer (BC) treatment is critical for women of reproductive age. Accurate risk assessment is essential for fertility counseling and preservation. Amenorrhoea as an infertility marker is unreliable due to endocrine therapies. Anti-Mullerian hormone (AMH) is a reliable fertility marker, but its role in assessing chemotherapy-induced loss of ovarian reserve in BC survivors remains underexplored.

Objective

This systematic review and meta-analysis evaluates AMH decline and the prevalence of low (AMH <1 ng/mL) and very low (<0.5 ng/mL) ovarian reserve in BC survivors <40 years old, 12-24 months post-chemotherapy, to quantify the gonadotoxic impact of BC treatments.

Methods

A systematic literature search of PubMed, Embase

SUBMITTER: Weidlinger S 

PROVIDER: S-EPMC12221882 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature